Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 4Active not recruiting 3Withdrawn 1Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3Leukemia, Hairy Cell 2Uterine Cervical Neoplasms 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Oropharyngeal Neoplasms 1Neoplasm, Residual 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1Anus Neoplasms 1

Interventions

Dexamethasone 115Lenalidomide 74daratumumab 57Bortezomib 52carfilzomib 41Calcium Dobesilate 36pomalidomide 35Cyclophosphamide 26isatuximab 23belantamab mafodotin 22Specimen Handling 20Biopsy 20Magnetic Resonance Spectroscopy 17dexamethasone acetate 13dexamethasone 21-phosphate 13auricularum 12ixazomib 11iberdomide 11fludarabine 11elotuzumab 11selinexor 10Melphalan 10fludarabine phosphate 8talquetamab 7X-Rays 7trametinib 6nirogacestat 6venetoclax 5Thalidomide 5Nuclear Medicine Department, Hospital 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Multiple Myeloma × Diphenhydramine × Clear all
NCT04268498 2026-03-24

ADVANCE

University of Miami

Phase 2 Active not recruiting
310 enrolled
Plasma cell

Multiple Myeloma

NCT05704049 2025-12-29

IZALCO

Sanofi

Phase 2 Active not recruiting
118 enrolled
Plasma cell

Multiple Myeloma

NCT04270409 2025-12-12

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Sanofi

Phase 3 Active not recruiting
337 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡